CONCORD, Calif. & DENVER--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that Bonfils Blood
Center has signed a three-year purchase agreement for the INTERCEPT
Blood System for platelets and plasma. Bonfils provides blood and blood
products to more than 100 hospitals and healthcare facilities across
Colorado and beyond, supplying approximately 20,000 platelet and 25,000
plasma units per year. Bonfils is an affiliate of Blood Systems Inc.,
one of the largest blood product and service providers in the U.S.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150713005506/en/
“We are excited to partner with Cerus to make INTERCEPT pathogen
reduction another important option for our healthcare clients as we work
in collaboration to deliver on our mission to ‘save and enhance lives
through transfusion medicine excellence,’” said Bryan Krueger, Bonfils
Blood Center President and Chief Executive Officer.
“We are pleased to offer the use of INTERCEPT pathogen reduction to
enhance the quality of care provided at the hospitals we serve and for
the patients for which they provide treatment,” said Tuan Le, MD,
Medical Director and Vice President of Medical Affairs at Bonfils Blood
Center.
"Bonfils has been a valuable research partner for us, contributing
significantly to studies we've used to support our current FDA approvals
and also future product extensions," commented William "Obi" Greenman,
Cerus’ President and Chief Executive Officer. "We are pleased to expand
this relationship and now become their pathogen reduction supplier."
ABOUT BONFILS BLOOD CENTER
For more than 70 years, Bonfils Blood Center has held a presence in this
community as one of Colorado’s top nonprofit healthcare organizations.
Bonfils is proud to have become a trusted community resource and source
of hope for those in their time of need as well as an outlet for its
neighbors wanting to give back through blood, marrow and financial
donations. In order to meet the needs of more than 100 healthcare
facilities Bonfils serves and to be prepared for unexpected events,
Bonfils must collect more than 3,000 blood donations each week. For
information about Bonfils Blood Center please call 303.366.2000 or visit www.bonfils.org
or look for Bonfils on Facebook, Twitter and Instagram.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood safety. The INTERCEPT Blood System is designed to reduce the
risk of transfusion-transmitted infections by inactivating a broad range
of pathogens such as viruses, bacteria and parasites that may be present
in donated blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established transfusion
threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria,
as well as emerging pathogens such as chikungunya, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in the United States, Europe, the Commonwealth of
Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150713005506/en/
Source: Cerus Corporation